Cutaneous T-cell lymphoma (CTCL) is a group of blood cancers in which certain white blood cells, called T cells, become malignant and accumulate in the skin. Unlike most lymphomas that start in lymph nodes, CTCL begins as a skin problem, often looking like a rash, dry patches, or eczema that won’t go away. It’s uncommon, and in many cases it progresses slowly over years or even decades, though more aggressive forms exist.
How CTCL Develops
T cells are part of your immune system. They normally circulate through your blood, lymph nodes, and tissues looking for infections. In CTCL, a group of T cells (usually a specific subtype called CD4+ T cells) becomes cancerous and migrates into the skin, where it multiplies. These malignant cells lose some of the surface markers that healthy T cells carry and gain others that help them home in on skin tissue and evade immune detection.
In early disease, the cancerous cells stay confined to the skin. Over time, they can spread to lymph nodes, the bloodstream, and occasionally internal organs. This progression isn’t inevitable, and many people with early-stage disease never advance beyond skin involvement.
The Two Main Subtypes
CTCL encompasses several subtypes, but two account for the vast majority of cases.
Mycosis fungoides is the most common form. Despite the name, it has nothing to do with a fungal infection. It typically moves through three recognizable phases. In the patch phase, flat, reddened areas appear on the skin that resemble eczema or psoriasis. In the plaque phase, those areas become raised, thickened, and firm. In the tumor phase, larger nodules develop on the skin, sometimes breaking open into ulcers that can become infected. Not everyone progresses through all three phases. Many people stay in the patch stage for years, and patches are always present even when the disease advances. If tumors appear without any patches, doctors consider other diagnoses.
Sézary syndrome is a more aggressive, leukemic form. It’s defined by three features: widespread redness covering more than 80% of the body’s surface, swollen lymph nodes, and large numbers of cancerous T cells circulating in the blood. Those circulating cells, called Sézary cells, have a distinctive wrinkled, brain-like nucleus visible under a microscope. Sézary syndrome occurs almost exclusively in adults and carries a worse prognosis than mycosis fungoides.
Symptoms Beyond the Skin
The visible skin changes are the hallmark of CTCL, but the symptom that often causes the most distress is intense, persistent itching. Up to 88% of all CTCL patients experience significant itch, rising to 94% in those with Sézary syndrome. This itching is driven by chemical signals released by the cancerous cells and the inflammatory environment they create, particularly substances like tryptase and a nerve-signaling molecule called Substance P.
What makes CTCL-related itching especially difficult is that it typically doesn’t respond well to standard remedies like topical steroids or antihistamines. For many patients, managing itch requires treating the underlying lymphoma itself rather than targeting the itch alone.
How CTCL Is Diagnosed
Diagnosis is notoriously tricky because early CTCL looks like many common skin conditions. It’s not unusual for people to be treated for eczema, psoriasis, or dermatitis for years before a biopsy reveals lymphoma. The process typically requires multiple steps.
A skin biopsy is the starting point. Pathologists examine the tissue under a microscope, looking for malignant T cells clustered in characteristic patterns within the skin. They then use a technique called immunophenotyping, which identifies specific proteins on the surface of the abnormal cells (markers like CD4, CD3, and CD5 on T cells) to confirm they’re cancerous T cells rather than another cell type. In ambiguous cases, molecular testing looks for evidence that the T cells share a single genetic origin, a T-cell clone, by analyzing rearrangements in T-cell receptor genes using PCR or next-generation sequencing.
Finding a clone in a single biopsy isn’t enough on its own. To confirm a cancer diagnosis, the same clone needs to be identified in multiple locations or samples. For Sézary syndrome specifically, diagnosis requires at least 1,000 Sézary cells per cubic millimeter of blood, a highly elevated ratio of CD4+ to CD8+ cells (greater than 10:1), or molecular evidence of a circulating T-cell clone.
Staging and Prognosis
CTCL is staged based on how much skin is affected, whether lymph nodes are involved, whether cancerous cells appear in the blood, and whether the disease has reached internal organs. A study of 525 patients published in JAMA Dermatology illustrates how dramatically stage affects outlook:
- Stage IA (limited patches covering less than 10% of the skin): 96% five-year survival
- Stage IB/IIA (more extensive skin involvement or mildly abnormal lymph nodes): 73% five-year survival
- Stage IIB/III (skin tumors or erythroderma): 44% five-year survival
- Stage IV (spread to lymph nodes, blood, or organs): 27% five-year survival
The key takeaway is that early-stage disease has a very favorable prognosis. Most people diagnosed at stage IA have a near-normal life expectancy. The challenge is that the disease can be difficult to diagnose early, and progression, while slow, shifts the outlook considerably.
Treatment for Early-Stage Disease
When CTCL is limited to the skin, treatment focuses directly on the skin. These approaches are called skin-directed therapies, and for many patients they’re the only treatment needed for years.
Topical corticosteroids are often the first step, helping to reduce redness and inflammation in patches and thin plaques. Phototherapy, which uses controlled ultraviolet light exposure, plays a central role. Two forms are commonly used: narrowband UVB, which penetrates the upper skin layers and works well for patches, and PUVA, which combines a light-sensitizing medication with UVA light to reach deeper into the skin for thicker plaques. Both have strong long-term safety and efficacy data.
Treatment for Advanced Disease
When CTCL progresses beyond the skin or doesn’t respond to skin-directed therapy, systemic treatments enter the picture. These work throughout the body rather than targeting individual lesions.
One distinctive option is extracorporeal photopheresis, an FDA-approved procedure particularly useful for Sézary syndrome. Blood is drawn, the white blood cells are separated and exposed to ultraviolet light with a sensitizing agent, then returned to the body. This process appears to trigger an immune response against the cancerous cells and can also help with itching.
Other systemic options include retinoid-type medications that influence how cells grow and differentiate, drugs that modify gene expression inside cancer cells by altering how DNA is packaged, and targeted antibody-based therapies that bind to proteins on the surface of the malignant T cells to destroy them. Treatment is generally tailored to the individual, starting with less toxic options and escalating based on response. Because CTCL is a chronic disease in most cases, the goal is often long-term control rather than cure, balancing effectiveness against side effects over what can be a very long treatment timeline.